Session Invited Program IM/TH- Radiopharmaceutical Therapy

Simulation Tools for Multiscale Modeling for Radiopharmaceutical Applications

Description

At the subcellular scale, Monte Carlo track-structure (MCTS) has demonstrated good accuracy for modeling the initial radiation-induced biological damage by providing a detailed characterization of the spatiotemporal complex structure of ionizing radiation. At a much larger scale, Condensed-History MC (CHMC) has been instrumental in the technological advancement of radiotherapeutic devices, patient dosimetry, and reference dosimetry in radiotherapy. While there exist differences in space and time characterization between MCTS and CHMC, tools using those methods have evolved significantly, enabling detailed modeling of biological damage by simulating the physics process of energy deposition and subsequent chemical stages of water radiolysis. However, there exist limitations in terms of scalability and accountability of biological cell behavior. Agent-based software allows scalability and accounts for cell behavior, but lacks sufficient resolution to determine radiation-induced damage from first principles. This session aims to revisit the current tools used for radiopharmaceutical therapy (RPT) modeling, existing capabilities and limitations of MCTS, CHMC, and Agent-based algorithms, the potential impact of RTP from coupling both algorithms, the requirements to accomplish coupling, and methods for improving computational speed.

People

Related

Similar sessions

Session Invited Program Room 205
Jul 19 · 13:15
Dosimetry in Radiopharmaceutical Therapy: Why it matters

This educational session will address why dosimetry is central to modern radiopharmaceutical therapy. It will highlight how fixed-activity approaches emerged historically and why they are increasingly insufficient in the context...

Robin Peter, PhD Alejandro Bertolet, PhD Alejandro Bertolet, PhD
IM/TH- Radiopharmaceutical Therapy 0 people interested
Session Invited Program Room 205
Jul 19 · 14:25
Dosimetry in Radiopharmaceutical Therapy: How to Do It

This session will present a structured, educational overview of how to perform patient-specific dosimetry in radiopharmaceutical therapy, using AAPM TG-381 as a reference framework. The first part will walk through generalizable...

Alejandro Bertolet, PhD David P. Adam, PhD, MS
IM/TH- Radiopharmaceutical Therapy 0 people interested
Session Invited Program Room 205
Jul 20 · 08:40
Basic Y-90 Image-Based Dosimetry Workshop: Past and Present

Interactive, educational, hands-on session (60 min total). The first part focuses on participant interaction with the web demo; the second part provides an expert synthesis of results. Emphasis is on building intuition rather tha...

Nichole Millward Maughan, PhD Alejandro Bertolet, PhD
IM/TH- Radiopharmaceutical Therapy 0 people interested
Session Invited Program Room 205
Jul 20 · 13:15
A Primer on Radiopharmaceutical Therapy Radiobiology

Radiopharmaceutical therapy (RPT) is re-shaping how radiation is used to combat cancer since it provides a way to deliver radiation systemically. Due to its impactful clinical applications, RPT has been approved by the FDA to tre...

Alejandro Bertolet, PhD Robin Peter, PhD Gabriel O. Sawakuchi, PhD
IM/TH- Radiopharmaceutical Therapy 0 people interested
Session Invited Program Room 205
Jul 20 · 16:00
Personalized Dosimetry in Clinical Trials for Beta-Emitting Radiopharmaceutical Dosimetry

Personalized dosimetry in radiopharmaceutical therapy (RPT) is gaining strong interest because fixed-activity regimens often fail to capture the large variability in how patients respond to the treatment. Growing evidence shows c...

Robert Francois Hobbs, PhD Alejandro Bertolet, PhD Carlos Huesa-Berral, PhD
IM/TH- Radiopharmaceutical Therapy 0 people interested
Session Invited Program Room 205
Jul 20 · 17:10
Targeted radiation from within: the expanding role of radiopharmaceutical therapy

As precision oncology evolves, the goal is for RPT to be viewed as a bridge between nuclear medicine, radiation oncology and medical oncology for the benefit of patients with cancer. However, challenges remain related to items, s...

Dandan Zheng, PhD Alejandro Bertolet, PhD Indrin J. Chetty, PhD
IM/TH- Radiopharmaceutical Therapy 0 people interested